Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis

Zhao, Zinan; Hu, Xin; Zhang, Yatong; Liu, Deping

doi:10.18433/jpps31197

Cited by 3 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these consistent benefits were not observed when compared with ezetimibe (10,11). Alirocumab and evolocumab showed a reduction in cardiovascular disease, myocardial infarction, and stroke compared to placebo, with varying effects on mortality (15,20,21). PCSK9 inhibitors showed a greater reduction in LDL-C levels compared to ezetimibe, with no significant differences between doses (14)(15)(16).…”

Section: Safety and Efficacy Of Pcsk9 Inhibitor Treatmentmentioning

confidence: 99%

PCSK9 inhibition: from effectiveness to cost-effectiveness

Mercep,

Strikic,

Hrabac

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Dyslipidaemia is a complex disorder characterised by abnormal lipid levels in the blood, including cholesterol and triglycerides, and plays an important role in the development of atherosclerotic cardiovascular disease. Most risk factors for cardiovascular disease are modifiable, and dyslipidaemia is a key factor among them. It can result from a combination of genetic and environmental factors. A distinction is made between primary dyslipidaemia, which is mainly caused by inherited genetic changes, and secondary dyslipidaemia, which is due to underlying diseases or certain medications. The treatment of dyslipidaemia has evolved over the years. In the past, statins were the first choice, but newer drugs, such as proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, have gained prominence due to their effectiveness in lowering lipids. Although recent guidelines recommend PCSK9 inhibitors for high-risk patients and patients who cannot tolerate statins, their widespread use is limited because of cost. Several meta-analyses have confirmed the efficacy and safety of PCSK9 inhibitors and have shown a significant reduction in low-density lipoprotein (LDL) cholesterol levels. However, the long-term side effects and interactions with other risk factors for cardiovascular disease remain uncertain. In addition, cost-effectiveness analyses have shown mixed results, with some countries considering PCSK9 inhibitors to be cost-effective for certain patient groups, while others consider them less economical. Meanwhile, initial data from patients using PCSK9 inhibitors support the results of the clinical trials. To summarise, PCSK9 inhibitors represent a revolutionary solution for lowering LDL cholesterol, but their cost-effectiveness remains controversial. Despite the controversy, they offer clear benefits for high-risk patients and should therefore be considered in the treatment of dyslipidaemia.

show abstract

Section: Safety and Efficacy Of Pcsk9 Inhibitor Treatmentmentioning

confidence: 99%

PCSK9 inhibition: from effectiveness to cost-effectiveness

Mercep,

Strikic,

Hrabac

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes

Marouf

Iqbal

Mohamad

et al. 2022

Clinical Therapeutics

View full text Add to dashboard Cite

A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease

Rajabian

McCloskey

Jamialahmadi

et al. 2023

Reviews in the Neurosciences

View full text Add to dashboard Cite

There is a train of thought that lipid therapies may delay or limit the impact of neuronal loss and poor patient outcomes of neurodegenerative diseases (NDDs). A variety of medicines including lipid lowering modifiers (LLMs) are prescribed in NDDs. This paper summarizes the findings of clinical and observational trials including systematic reviews and meta-analyses relating to LLM use in NDDs published in the last 15 years thus providing an up-to-date evidence pool. Three databases were searched PubMed, CINAHL, and Web of Science using key terms relating to the review question. The findings confirm the benefit of LLMs in hyperlipidemic patients with or without cardiovascular risk factors due to their pleotropic effects. In NDDs LLMs are proposed to delay disease onset and slow the rate of progression. Clinical observations show that LLMs protect neurons from α-synuclein, tau, and Aβ toxicity, activation of inflammatory processes, and ultimately oxidative injury. Moreover, current meta-analyses and clinical trials indicated low rates of adverse events with LLMs when used as monotherapy. LLMs appear to have favorable safety and tolerability profiles with few patients stopping treatment due to severe adverse effects. Our collated evidence thus concludes that LLMs have a role in NDDs but further work is needed to understand the exact mechanism of action and reach more robust conclusions on where and when it is appropriate to use LLMs in NDDs in the clinic.

show abstract

Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis

Cited by 3 publications

References 25 publications

PCSK9 inhibition: from effectiveness to cost-effectiveness

PCSK9 inhibition: from effectiveness to cost-effectiveness

Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes

A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease

Contact Info

Product

Resources

About